Cara Therapeutics (NASDAQ:CARA) had its price objective lifted by Stifel Nicolaus to $20.00 in a research note issued to investors on Wednesday, May 23rd. They currently have a buy rating on the biopharmaceutical companys stock.
CARA has been the topic of several other reports. HC Wainwright set a $22.00 price target on shares of Cara Therapeutics and gave the company a buy rating in a report on Monday, March 19th. Janney Montgomery Scott raised shares of Cara Therapeutics from a neutral rating to a buy rating and lowered their price target for the company from $27.00 to $21.00 in a report on Monday, February 12th. BidaskClub downgraded shares of Cara Therapeutics from a hold rating to a sell rating in a research report on Tuesday, March 20th. Zacks Investment Research upgraded shares of Cara Therapeutics from a sell rating to a hold rating in a research report on Wednesday, March 21st. Finally, ValuEngine raised shares of Cara Therapeutics from a sell rating to a hold rating in a research note on Tuesday, February 13th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the companys stock. The stock presently has an average rating of Buy and an average target price of $24.37.
Shares of Cara Therapeutics opened at $16.07 on Wednesday, MarketBeat reports. The company has a market capitalization of $520.58 million, a P/E ratio of -8.64 and a beta of 3.03. Cara Therapeutics has a 52 week low of $11.11 and a 52 week high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.47) by ($0.04). analysts forecast that Cara Therapeutics will post -2.17 EPS for the current fiscal year.
In related news, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of Cara Therapeutics stock in a transaction on Friday, June 1st. The shares were sold at an average price of $15.49, for a total transaction of $46,470.00. Following the sale, the senior vice president now directly owns 107,000 shares in the company, valued at approximately $1,657,430. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in Cara Therapeutics by 25.6% in the fourth quarter. BlackRock Inc. now owns 2,207,407 shares of the biopharmaceutical companys stock valued at $27,018,000 after purchasing an additional 449,334 shares during the period. Disciplined Growth Investors Inc. MN boosted its holdings in shares of Cara Therapeutics by 1.4% in the fourth quarter. Disciplined Growth Investors Inc. MN now owns 861,219 shares of the biopharmaceutical companys stock valued at $10,541,000 after acquiring an additional 12,069 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Cara Therapeutics by 3.7% in the fourth quarter. Franklin Resources Inc. now owns 450,500 shares of the biopharmaceutical companys stock valued at $5,514,000 after acquiring an additional 16,000 shares in the last quarter. Nexthera Capital LP purchased a new stake in shares of Cara Therapeutics in the first quarter valued at about $4,346,000. Finally, ETF Managers Group LLC boosted its holdings in shares of Cara Therapeutics by 165.8% in the first quarter. ETF Managers Group LLC now owns 337,486 shares of the biopharmaceutical companys stock valued at $3,992,000 after acquiring an additional 210,534 shares in the last quarter. Institutional investors own 54.42% of the companys stock.
This article provided by NewsEdge.